Fortress Biotech, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Fortress Biotech, Inc. (FBIO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$9.91 million for the 12-month period ending 2019-12-31, per its 10-K/A filed 2021-04-09.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2021-04-09
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2018-12-31 was -$332.00K.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2018-09-30 was $0.00.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2018-06-30 was -$2.22M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2018-03-31 was -$1.86M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2019 was -$9.91M.
- Fortress Biotech, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2018 was -$4.41M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$9.91M 10-K/A · filed 2021-04-09 | |||
| 2018-12-31 | -$332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$332.00K derived: sum of 2 quarters · filed 2020-03-16 | -$2.55M derived: sum of 3 quarters · filed 2020-03-16 | -$4.41M 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$2.22M derived: sum of 2 quarters · filed 2018-11-09 | -$4.08M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$4.08M 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | -$1.86M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |